Catalent (CTLT)
(Delayed Data from NYSE)
$56.19 USD
-0.20 (-0.35%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $56.15 -0.04 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CTLT 56.19 -0.20(-0.35%)
Will CTLT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CTLT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTLT
Why Is Catalent (CTLT) Up 0.4% Since Last Earnings Report?
Catalent's (CTLT) Latest Partnership to Boost Clinical Trials
CTLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
Other News for CTLT
Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (RLAY), Catalent (CTLT) and Pediatrix Medical Group (MD)
Ardena appoints Jeremie Trochu as Chief Executive Officer
Medpace: Clear Winner If China Blockade Succeeds
Catalent’s Strategic Merger and Executive Compensation Plans
Catalent shareholders approve acquisition by Novo Holdings